Vaxart says preclinical study shows 100% H5N1 protection in ferrets

Vaxart said its second-generation oral mucosal vaccine candidate VXA-H5-02 induced cross-neutralizing antibodies, reduced viral load, and completely protected against a lethal H5N1 challenge in a ferret model.